Is Evoke Pharma, Inc. overvalued or undervalued?

As of 10 November 2021, Evoke Pharma, Inc. has moved from a grade of does not qualify to risky. The company is currently overvalued given its financial metrics and peer comparisons. Key ratios include a Price to Book Value of 0.75, an EV to EBIT of 0.63, and an EV to EBITDA of 0.63, which indicate significant valuation concerns relative to its earnings and assets.
In comparison with its peers, Evoke Pharma's EV to EBITDA ratio of -0.2076 is notably worse than Agile Therapeutics, Inc. at -0.5982 and Bellerophon Therapeutics, Inc. at 0.4464, highlighting its underperformance in generating earnings relative to its enterprise value. Additionally, while the company has shown a YTD return of 14.93%, it has significantly lagged behind the S&P 500's 12.22% return, and its long-term performance is concerning with a 5Y return of -99.28%.